PTC Therapeutics, Inc. Stock News

WARREN, N.J. , Aug. 21, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: Cantor Global Healthcare Conference 2025 Wednesday, Sept.

Company is positioned for growth with SEPHIENCE, approved for PKU in the US and Europe, and pending decisions in Japan and Brazil. Votoplam (PTC518) for Huntington's Disease shows promising phase 2 results; a key FDA meeting in Q4 2025 could enable Accelerated Approval and set a phase 3 trial design. Strong partnership with Novartis provides financial strength and development support for votopl...

The U.S. Food and Drug Administration has declined to approve PTC Therapeutics' drug to treat a rare genetic disorder that causes progressive damage to the nervous system, the company said on Tuesday, delaying a potential treatment for patients with limited treatment options.

WARREN, N.J. , Aug. 19, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) related to the New Drug Application (NDA) for vatiquinone for the treatment of children and adults living with Friedreich's ataxia.

PTC Therapeutics, Inc. (NASDAQ:PTCT ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Ellen Cavaleri - Corporate Participant Eric Pauwels - Chief Business Officer Jarwei Fang - Corporate Participant Matthew B. Klein - CEO & Director Pierre Gravier - Chief Financial Officer Conference Call Participants Dingding Shi - Jefferies LLC, Research Division Huidong Wang -...

PTCT Earnings Beat but Sales Drop 4%

– European and FDA approval of Sephience™ (sepiapterin) with broad labeling for PKU – – Global launch underway in Europe and U.S. – – Total Q2 Revenue of $179M – WARREN, N.J. , Aug. 7, 2025 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the second quarter ended June 30, 2025.

The U.S. Food and Drug Administration has approved PTC Therapeutics' oral drug to treat a rare inherited metabolic disorder that prevents the body from properly breaking down certain amino acids, the company said on Monday.